Compare Amgen, Inc. (AMGN) vs Johnson Controls International PLC (JCI) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Amgen, Inc. vs Johnson Controls International PLC — how do they compare? Amgen, Inc. trades at $363.66 (market cap $196.12B), while Johnson Controls International PLC trades at $142.07 (market cap $87.13B). The key difference: Amgen, Inc. is far larger — about 2.3× Johnson Controls International PLC's market cap, and Amgen, Inc. pays the higher dividend (2.77%). Which is the better fit depends on your goals.
| AMGN | JCI | |
|---|---|---|
Market Cap | $196.12B | $87.13B |
Sector | Health | Industrials |
52-Week High | $388.16 | $148.21 |
52-Week Low | $271.18 | $103.24 |
Enterprise Value | $241.41B | $95.96B |
Dividend Yield | 2.77% | 1.12% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AMGN trades at $363.39, down slightly by 0.06% today, with a bullish technical signal from moving averages. The company reported strong Q1 2026 earnings, beating estimates with EPS of $5.15 versus $4.77 expected. Revenue grew to $36.75B in 2025, with a net income margin of 20.96%. Recent news includes a favorable court ruling blocking a price cap on Enbrel in Colorado, but regulatory challenges persist for Tavneos in Europe.
The outlook remains positive due to consistent earnings beats and a diversified product portfolio, though risks include regulatory setbacks and competitive pressures. Analyst consensus is bullish with a 57.9% buy rating and a price target of $357.38, slightly below the current price, indicating potential for stability with upside from pipeline developments.
Johnson Controls International (JCI) trades at $142.81, up 1.62% on the day, with a bearish technical signal despite recent earnings beats. The company shows strong profitability with a net income margin of 14.45% and a consensus analyst price target of $153.67. Recent news highlights expansion in data center cooling and smart home markets, supported by a dividend of $0.40 per share payable in July 2026.
JCI's outlook is supported by earnings momentum and strategic acquisitions, but risks include high valuation multiples and bearish technical indicators. The stock offers potential upside to analyst targets, though investors should monitor debt levels and market sentiment shifts.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Amgen, Inc.
Amgen is a leader in biotechnology-based human therapeutics, with historical expertise in renal disease and cancer supportive-care products. Flagship drugs include red blood cell boosters Epogen and Aranesp, immune system boosters Neupogen and Neulasta, and Enbrel and Otezla for inflammatory diseases. Amgen introduced its first cancer therapeutic, Vectibix, in 2006 and markets bone-strengthening drug Prolia/Xgeva (approved 2010) and Evenity (2019). The acquisition of Onyx bolstered the firm's therapeutic oncology portfolio with Kyprolis. Recent launches include Repatha (cholesterol-lowering), Aimovig (migraine), Lumakras (lung cancer), and Tezspire (asthma). Amgen's biosimilar portfolio includes Mvasi (biosimilar Avastin), Kanjinti (biosimilar Herceptin), and Amgevita (biosimilar Humira).
Read more on AMGN →About Johnson Controls International PLC
Johnson Controls manufactures, installs, and services HVAC systems, building management systems and controls, industrial refrigeration systems, and fire and security solutions. Commercial HVAC accounts for about 40% of sales, fire and security also represents 40% of sales, and residential HVAC, industrial refrigeration, and other solutions account for the remaining 20% of revenue. In fiscal 2021, Johnson Controls generated over $23.5 billion in revenue.
Read more on JCI →
